Anavex Life Sciences (AVXL) Stock Is Rocketing: Will Innovative Drug Push Up The Stock?

Today, Anavex  (AVXL) stock is surging 4.29% in the last trading session, it has increased in value from $21.23 to $22.14. The estimated price is pleased to be 11.56% higher than current. Moreover, over the last month, the company’s stock has been gradually surged from $11.92 to $22.14. Today, price is growing up amid recent news.
3 Great Reasons to Buy Gilead Sciences Stock | The Motley FoolThe company announced today that a predictive response biomarker based on SSIGMA R1 mRNA expression was shown to be strongly associated with responses at main clinical efficacy endpoints in the US. In adult individuals with Rett syndrome, a phase 2 randomized, double-blind, placebo-controlled study of ANAVEX® 2-73 (blarcamesin) was conducted.

Anavar plans to meet with the FDA to explore a route for approval based on this compelling biomarker and results from the American Phase 2 (ANAVAR ® 2-73-RS-001)7 trial in adult patients with Rett syndrome. There are currently no FDA-approved medicines to treat Rett syndrome, that’s why such drugs could greatly boost stocks to the high. Investors just expecting, when these drugs will be approved by FDA and enter the sell market.

Jack Dawkins

Finance and Tech Contributor

Want Hot Stocks?    Yes. I Love Them No thanks